Crossject Société Anonyme, headquartered in France, is a pioneering company in the pharmaceutical industry, specialising in the development of innovative drug delivery systems. Founded in 2007, Crossject has made significant strides in creating its unique needle-free injection technology, which enhances patient comfort and compliance. The company focuses on several therapeutic areas, including pain management and emergency medicine, with its flagship product, Zeneo, designed to provide rapid and effective medication delivery. Crossject's commitment to innovation has positioned it as a leader in the market, with notable achievements in securing partnerships and advancing its product pipeline. With operations extending across Europe and beyond, Crossject continues to redefine the standards of drug administration, making healthcare more accessible and efficient.
How does Crossject Société Anonyme's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Mean score of companies in the Medical Device Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Crossject Société Anonyme's score of 26 is lower than 53% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Crossject Société Anonyme, headquartered in France, currently does not report any carbon emissions data, as indicated by the absence of specific figures in kg CO2e. Furthermore, there are no documented reduction targets or climate pledges associated with the company. This lack of emissions data and commitments suggests that Crossject may not yet have established a formal framework for addressing its carbon footprint or engaging in climate action initiatives. As the industry increasingly prioritises sustainability, it will be essential for Crossject to consider developing and communicating its climate commitments to align with global standards and expectations.
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Crossject Société Anonyme has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
